0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Short-acting Insulin Market Research Report 2026
Published Date: 2026-03-11
|
Report Code: QYRE-Auto-1G17998
Home | Market Reports
Global Short acting Insulin Market Research Report 2024
BUY CHAPTERS

Global Short-acting Insulin Market Research Report 2026

Code: QYRE-Auto-1G17998
Report
2026-03-11
Pages:123
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Short-acting Insulin Market

The global Short-acting Insulin market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Short-acting Insulin competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.It is used to control blood Short-acting insulin is a type of insulin that is designed to have a rapid onset and relatively short duration of action in the body.This type of insulin starts working within about 15 to 30 minutes after injection,and continues to lower blood sugar for approximately 3 to 6 hours.Its primary function is to manage blood sugar levels by facilitating the uptake of glucose into cells.
The North American market for Short-acting Insulin is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Short-acting Insulin is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Short-acting Insulin include Eli Lilly, Novo Nordisk, Biocon Biologics, Sanofi, Wockhardt, Bayer, Pfizer, BASF, Abbott Laboratories, Tonghua Dongbao Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Short-acting Insulin market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Short-acting Insulin. The Short-acting Insulin market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Short-acting Insulin market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Short-acting Insulin manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Short-acting Insulin Market Report

Report Metric Details
Report Name Short-acting Insulin Market
Segment by Type
  • Regular Insulin
  • Biosynthetic Human Insulin
  • Recombinant Human Insulin
  • Other
by Application
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Complications of Diabetes
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Eli Lilly, Novo Nordisk, Biocon Biologics, Sanofi, Wockhardt, Bayer, Pfizer, BASF, Abbott Laboratories, Tonghua Dongbao Pharmaceutical, Zhuhai United Pharmaceutical, Sinovac Biotech, Wanbang Biopharmaceuticals, HTBT
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Short-acting Insulin manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Short-acting Insulin sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Short-acting Insulin Market report?

Ans: The main players in the Short-acting Insulin Market are Eli Lilly, Novo Nordisk, Biocon Biologics, Sanofi, Wockhardt, Bayer, Pfizer, BASF, Abbott Laboratories, Tonghua Dongbao Pharmaceutical, Zhuhai United Pharmaceutical, Sinovac Biotech, Wanbang Biopharmaceuticals, HTBT

What are the Application segmentation covered in the Short-acting Insulin Market report?

Ans: The Applications covered in the Short-acting Insulin Market report are Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Complications of Diabetes, Other

What are the Type segmentation covered in the Short-acting Insulin Market report?

Ans: The Types covered in the Short-acting Insulin Market report are Regular Insulin, Biosynthetic Human Insulin, Recombinant Human Insulin, Other

1 Short-acting Insulin Market Overview
1.1 Product Definition
1.2 Short-acting Insulin by Type
1.2.1 Global Short-acting Insulin Market Value by Type: 2025 vs 2032
1.2.2 Regular Insulin
1.2.3 Biosynthetic Human Insulin
1.2.4 Recombinant Human Insulin
1.2.5 Other
1.3 Short-acting Insulin by Application
1.3.1 Global Short-acting Insulin Market Value by Application: 2025 vs 2032
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.3.4 Gestational Diabetes
1.3.5 Complications of Diabetes
1.3.6 Other
1.4 Global Short-acting Insulin Market Size Estimates and Forecasts
1.4.1 Global Short-acting Insulin Revenue 2021–2032
1.4.2 Global Short-acting Insulin Sales 2021–2032
1.4.3 Global Short-acting Insulin Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Short-acting Insulin Market Competition by Manufacturers
2.1 Global Short-acting Insulin Sales Market Share by Manufacturers (2021–2026)
2.2 Global Short-acting Insulin Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Short-acting Insulin Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Short-acting Insulin, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Short-acting Insulin, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Short-acting Insulin, Product Types and Applications
2.7 Global Key Manufacturers of Short-acting Insulin, Date of Entry into the Industry
2.8 Global Short-acting Insulin Market Competitive Situation and Trends
2.8.1 Global Short-acting Insulin Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Short-acting Insulin Players Market Share by Revenue
2.8.3 Global Short-acting Insulin Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Short-acting Insulin Market Scenario by Region
3.1 Global Short-acting Insulin Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Short-acting Insulin Sales by Region: 2021–2032
3.2.1 Global Short-acting Insulin Sales by Region: 2021–2026
3.2.2 Global Short-acting Insulin Sales by Region: 2027–2032
3.3 Global Short-acting Insulin Revenue by Region: 2021–2032
3.3.1 Global Short-acting Insulin Revenue by Region: 2021–2026
3.3.2 Global Short-acting Insulin Revenue by Region: 2027–2032
3.4 North America Short-acting Insulin Market Facts & Figures by Country
3.4.1 North America Short-acting Insulin Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Short-acting Insulin Sales by Country (2021–2032)
3.4.3 North America Short-acting Insulin Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting Insulin Market Facts & Figures by Country
3.5.1 Europe Short-acting Insulin Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Short-acting Insulin Sales by Country (2021–2032)
3.5.3 Europe Short-acting Insulin Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting Insulin Market Facts & Figures by Region
3.6.1 Asia Pacific Short-acting Insulin Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Short-acting Insulin Sales by Region (2021–2032)
3.6.3 Asia Pacific Short-acting Insulin Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting Insulin Market Facts & Figures by Country
3.7.1 Latin America Short-acting Insulin Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Short-acting Insulin Sales by Country (2021–2032)
3.7.3 Latin America Short-acting Insulin Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Short-acting Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting Insulin Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Short-acting Insulin Sales by Country (2021–2032)
3.8.3 Middle East and Africa Short-acting Insulin Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting Insulin Sales by Type (2021–2032)
4.1.1 Global Short-acting Insulin Sales by Type (2021–2026)
4.1.2 Global Short-acting Insulin Sales by Type (2027–2032)
4.1.3 Global Short-acting Insulin Sales Market Share by Type (2021–2032)
4.2 Global Short-acting Insulin Revenue by Type (2021–2032)
4.2.1 Global Short-acting Insulin Revenue by Type (2021–2026)
4.2.2 Global Short-acting Insulin Revenue by Type (2027–2032)
4.2.3 Global Short-acting Insulin Revenue Market Share by Type (2021–2032)
4.3 Global Short-acting Insulin Price by Type (2021–2032)
5 Segment by Application
5.1 Global Short-acting Insulin Sales by Application (2021–2032)
5.1.1 Global Short-acting Insulin Sales by Application (2021–2026)
5.1.2 Global Short-acting Insulin Sales by Application (2027–2032)
5.1.3 Global Short-acting Insulin Sales Market Share by Application (2021–2032)
5.2 Global Short-acting Insulin Revenue by Application (2021–2032)
5.2.1 Global Short-acting Insulin Revenue by Application (2021–2026)
5.2.2 Global Short-acting Insulin Revenue by Application (2027–2032)
5.2.3 Global Short-acting Insulin Revenue Market Share by Application (2021–2032)
5.3 Global Short-acting Insulin Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Company Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Eli Lilly Short-acting Insulin Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Novo Nordisk
6.2.1 Novo Nordisk Company Information
6.2.2 Novo Nordisk Description and Business Overview
6.2.3 Novo Nordisk Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Novo Nordisk Short-acting Insulin Product Portfolio
6.2.5 Novo Nordisk Recent Developments/Updates
6.3 Biocon Biologics
6.3.1 Biocon Biologics Company Information
6.3.2 Biocon Biologics Description and Business Overview
6.3.3 Biocon Biologics Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biocon Biologics Short-acting Insulin Product Portfolio
6.3.5 Biocon Biologics Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Company Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sanofi Short-acting Insulin Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Wockhardt
6.5.1 Wockhardt Company Information
6.5.2 Wockhardt Description and Business Overview
6.5.3 Wockhardt Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Wockhardt Short-acting Insulin Product Portfolio
6.5.5 Wockhardt Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Company Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bayer Short-acting Insulin Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Pfizer Short-acting Insulin Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 BASF
6.8.1 BASF Company Information
6.8.2 BASF Description and Business Overview
6.8.3 BASF Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 BASF Short-acting Insulin Product Portfolio
6.8.5 BASF Recent Developments/Updates
6.9 Abbott Laboratories
6.9.1 Abbott Laboratories Company Information
6.9.2 Abbott Laboratories Description and Business Overview
6.9.3 Abbott Laboratories Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Abbott Laboratories Short-acting Insulin Product Portfolio
6.9.5 Abbott Laboratories Recent Developments/Updates
6.10 Tonghua Dongbao Pharmaceutical
6.10.1 Tonghua Dongbao Pharmaceutical Company Information
6.10.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.10.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio
6.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
6.11 Zhuhai United Pharmaceutical
6.11.1 Zhuhai United Pharmaceutical Company Information
6.11.2 Zhuhai United Pharmaceutical Description and Business Overview
6.11.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio
6.11.5 Zhuhai United Pharmaceutical Recent Developments/Updates
6.12 Sinovac Biotech
6.12.1 Sinovac Biotech Company Information
6.12.2 Sinovac Biotech Description and Business Overview
6.12.3 Sinovac Biotech Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Sinovac Biotech Short-acting Insulin Product Portfolio
6.12.5 Sinovac Biotech Recent Developments/Updates
6.13 Wanbang Biopharmaceuticals
6.13.1 Wanbang Biopharmaceuticals Company Information
6.13.2 Wanbang Biopharmaceuticals Description and Business Overview
6.13.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio
6.13.5 Wanbang Biopharmaceuticals Recent Developments/Updates
6.14 HTBT
6.14.1 HTBT Company Information
6.14.2 HTBT Description and Business Overview
6.14.3 HTBT Short-acting Insulin Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 HTBT Short-acting Insulin Product Portfolio
6.14.5 HTBT Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting Insulin Industry Chain Analysis
7.2 Short-acting Insulin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting Insulin Production Mode & Process Analysis
7.4 Short-acting Insulin Sales and Marketing
7.4.1 Short-acting Insulin Sales Channels
7.4.2 Short-acting Insulin Distributors
7.5 Short-acting Insulin Customer Analysis
8 Short-acting Insulin Market Dynamics
8.1 Short-acting Insulin Industry Trends
8.2 Short-acting Insulin Market Drivers
8.3 Short-acting Insulin Market Challenges
8.4 Short-acting Insulin Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Short-acting Insulin Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Short-acting Insulin Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Short-acting Insulin Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Short-acting Insulin Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Short-acting Insulin Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Short-acting Insulin Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Short-acting Insulin Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Short-acting Insulin Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Short-acting Insulin, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Short-acting Insulin, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Short-acting Insulin, Product Types and Applications
 Table 12. Global Key Manufacturers of Short-acting Insulin, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Short-acting Insulin Companies by Tier (Tier 1, Tier 2, Tier 3), based on Short-acting Insulin Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Short-acting Insulin Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Short-acting Insulin Sales by Region (K Units), 2021–2026
 Table 18. Global Short-acting Insulin Sales Market Share by Region (2021–2026)
 Table 19. Global Short-acting Insulin Sales by Region (K Units), 2027–2032
 Table 20. Global Short-acting Insulin Sales Market Share by Region (2027–2032)
 Table 21. Global Short-acting Insulin Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Short-acting Insulin Revenue Market Share by Region (2021–2026)
 Table 23. Global Short-acting Insulin Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Short-acting Insulin Revenue Market Share by Region (2027–2032)
 Table 25. North America Short-acting Insulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Short-acting Insulin Sales by Country (K Units), 2021–2026
 Table 27. North America Short-acting Insulin Sales by Country (K Units), 2027–2032
 Table 28. North America Short-acting Insulin Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Short-acting Insulin Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Short-acting Insulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Short-acting Insulin Sales by Country (K Units), 2021–2026
 Table 32. Europe Short-acting Insulin Sales by Country (K Units), 2027–2032
 Table 33. Europe Short-acting Insulin Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Short-acting Insulin Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Short-acting Insulin Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Short-acting Insulin Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Short-acting Insulin Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Short-acting Insulin Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Short-acting Insulin Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Short-acting Insulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Short-acting Insulin Sales by Country (K Units), 2021–2026
 Table 42. Latin America Short-acting Insulin Sales by Country (K Units), 2027–2032
 Table 43. Latin America Short-acting Insulin Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Short-acting Insulin Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Short-acting Insulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Short-acting Insulin Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Short-acting Insulin Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Short-acting Insulin Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Short-acting Insulin Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Short-acting Insulin Sales (K Units) by Type (2021–2026)
 Table 51. Global Short-acting Insulin Sales (K Units) by Type (2027–2032)
 Table 52. Global Short-acting Insulin Sales Market Share by Type (2021–2026)
 Table 53. Global Short-acting Insulin Sales Market Share by Type (2027–2032)
 Table 54. Global Short-acting Insulin Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Short-acting Insulin Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Short-acting Insulin Revenue Market Share by Type (2021–2026)
 Table 57. Global Short-acting Insulin Revenue Market Share by Type (2027–2032)
 Table 58. Global Short-acting Insulin Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Short-acting Insulin Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Short-acting Insulin Sales (K Units) by Application (2021–2026)
 Table 61. Global Short-acting Insulin Sales (K Units) by Application (2027–2032)
 Table 62. Global Short-acting Insulin Sales Market Share by Application (2021–2026)
 Table 63. Global Short-acting Insulin Sales Market Share by Application (2027–2032)
 Table 64. Global Short-acting Insulin Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Short-acting Insulin Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Short-acting Insulin Revenue Market Share by Application (2021–2026)
 Table 67. Global Short-acting Insulin Revenue Market Share by Application (2027–2032)
 Table 68. Global Short-acting Insulin Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Short-acting Insulin Price (US$/Unit) by Application (2027–2032)
 Table 70. Eli Lilly Company Information
 Table 71. Eli Lilly Description and Business Overview
 Table 72. Eli Lilly Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Eli Lilly Short-acting Insulin Product
 Table 74. Eli Lilly Recent Developments/Updates
 Table 75. Novo Nordisk Company Information
 Table 76. Novo Nordisk Description and Business Overview
 Table 77. Novo Nordisk Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Novo Nordisk Short-acting Insulin Product
 Table 79. Novo Nordisk Recent Developments/Updates
 Table 80. Biocon Biologics Company Information
 Table 81. Biocon Biologics Description and Business Overview
 Table 82. Biocon Biologics Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Biocon Biologics Short-acting Insulin Product
 Table 84. Biocon Biologics Recent Developments/Updates
 Table 85. Sanofi Company Information
 Table 86. Sanofi Description and Business Overview
 Table 87. Sanofi Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Sanofi Short-acting Insulin Product
 Table 89. Sanofi Recent Developments/Updates
 Table 90. Wockhardt Company Information
 Table 91. Wockhardt Description and Business Overview
 Table 92. Wockhardt Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Wockhardt Short-acting Insulin Product
 Table 94. Wockhardt Recent Developments/Updates
 Table 95. Bayer Company Information
 Table 96. Bayer Description and Business Overview
 Table 97. Bayer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Bayer Short-acting Insulin Product
 Table 99. Bayer Recent Developments/Updates
 Table 100. Pfizer Company Information
 Table 101. Pfizer Description and Business Overview
 Table 102. Pfizer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Pfizer Short-acting Insulin Product
 Table 104. Pfizer Recent Developments/Updates
 Table 105. BASF Company Information
 Table 106. BASF Description and Business Overview
 Table 107. BASF Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. BASF Short-acting Insulin Product
 Table 109. BASF Recent Developments/Updates
 Table 110. Abbott Laboratories Company Information
 Table 111. Abbott Laboratories Description and Business Overview
 Table 112. Abbott Laboratories Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Abbott Laboratories Short-acting Insulin Product
 Table 114. Abbott Laboratories Recent Developments/Updates
 Table 115. Tonghua Dongbao Pharmaceutical Company Information
 Table 116. Tonghua Dongbao Pharmaceutical Description and Business Overview
 Table 117. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product
 Table 119. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
 Table 120. Zhuhai United Pharmaceutical Company Information
 Table 121. Zhuhai United Pharmaceutical Description and Business Overview
 Table 122. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Zhuhai United Pharmaceutical Short-acting Insulin Product
 Table 124. Zhuhai United Pharmaceutical Recent Developments/Updates
 Table 125. Sinovac Biotech Company Information
 Table 126. Sinovac Biotech Description and Business Overview
 Table 127. Sinovac Biotech Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. Sinovac Biotech Short-acting Insulin Product
 Table 129. Sinovac Biotech Recent Developments/Updates
 Table 130. Wanbang Biopharmaceuticals Company Information
 Table 131. Wanbang Biopharmaceuticals Description and Business Overview
 Table 132. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. Wanbang Biopharmaceuticals Short-acting Insulin Product
 Table 134. Wanbang Biopharmaceuticals Recent Developments/Updates
 Table 135. HTBT Company Information
 Table 136. HTBT Description and Business Overview
 Table 137. HTBT Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 138. HTBT Short-acting Insulin Product
 Table 139. HTBT Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Short-acting Insulin Distributors List
 Table 143. Short-acting Insulin Customers List
 Table 144. Short-acting Insulin Market Trends
 Table 145. Short-acting Insulin Market Drivers
 Table 146. Short-acting Insulin Market Challenges
 Table 147. Short-acting Insulin Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Short-acting Insulin
 Figure 2. Global Short-acting Insulin Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Short-acting Insulin Market Share by Type: 2025 & 2032
 Figure 4. Regular Insulin Product Picture
 Figure 5. Biosynthetic Human Insulin Product Picture
 Figure 6. Recombinant Human Insulin Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Short-acting Insulin Market Value by Application (US$ Million), 2021–2032
 Figure 9. Global Short-acting Insulin Market Share by Application: 2025 & 2032
 Figure 10. Type 1 Diabetes
 Figure 11. Type 2 Diabetes
 Figure 12. Gestational Diabetes
 Figure 13. Complications of Diabetes
 Figure 14. Other
 Figure 15. Global Short-acting Insulin Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 16. Global Short-acting Insulin Market Size (US$ Million), 2021–2032
 Figure 17. Global Short-acting Insulin Sales (K Units), 2021–2032
 Figure 18. Global Short-acting Insulin Average Price (US$/Unit), 2021–2032
 Figure 19. Short-acting Insulin Report Years Considered
 Figure 20. Short-acting Insulin Sales Share by Manufacturers in 2025
 Figure 21. Global Short-acting Insulin Revenue Share by Manufacturers in 2025
 Figure 22. Top 5 and Top 10 Global Short-acting Insulin Players: Market Share by Revenue in Short-acting Insulin in 2025
 Figure 23. Short-acting Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 24. Global Short-acting Insulin Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 25. North America Short-acting Insulin Sales Market Share by Country (2021–2032)
 Figure 26. North America Short-acting Insulin Revenue Market Share by Country (2021–2032)
 Figure 27. United States Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Canada Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Europe Short-acting Insulin Sales Market Share by Country (2021–2032)
 Figure 30. Europe Short-acting Insulin Revenue Market Share by Country (2021–2032)
 Figure 31. Germany Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. France Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. U.K. Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Italy Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Russia Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Asia Pacific Short-acting Insulin Sales Market Share by Region (2021–2032)
 Figure 37. Asia Pacific Short-acting Insulin Revenue Market Share by Region (2021–2032)
 Figure 38. China Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Japan Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. South Korea Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. India Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Australia Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. China Taiwan Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Southeast Asia Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Latin America Short-acting Insulin Sales Market Share by Country (2021–2032)
 Figure 46. Latin America Short-acting Insulin Revenue Market Share by Country (2021–2032)
 Figure 47. Mexico Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Brazil Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Argentina Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Colombia Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Middle East and Africa Short-acting Insulin Sales Market Share by Country (2021–2032)
 Figure 52. Middle East and Africa Short-acting Insulin Revenue Market Share by Country (2021–2032)
 Figure 53. Turkey Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Saudi Arabia Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. UAE Short-acting Insulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Global Sales Market Share of Short-acting Insulin by Type (2021–2032)
 Figure 57. Global Revenue Market Share of Short-acting Insulin by Type (2021–2032)
 Figure 58. Global Short-acting Insulin Price (US$/Unit) by Type (2021–2032)
 Figure 59. Global Sales Market Share of Short-acting Insulin by Application (2021–2032)
 Figure 60. Global Revenue Market Share of Short-acting Insulin by Application (2021–2032)
 Figure 61. Global Short-acting Insulin Price (US$/Unit) by Application (2021–2032)
 Figure 62. Short-acting Insulin Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture